Neurology Newsletter

Less disability progression with continuous treatment Data from the open-label extension of the EXPAND study of patients with secondary progressive multiple sclerosis (SPMS) showed that early treatment benefits with siponimod...

No serious opportunistic infections reported Relapsing multiple sclerosis (RMS) patients who had longer exposure to oral ozanimod HCl 1 mg (Zeposia) showed similar infection rates as patients who had ≤24 months’...

Five-year followup extends earlier findings Early elevated plasma neurofilament light (pNfL) — checked around the time of diagnosis — was associated with risk of sustained disability worsening in multiple sclerosis...

Effects generally greater among relapsing than non-relapsing patients in EXPAND trial The effects of siponimod (Mayzent) in secondary progressive multiple sclerosis (SPMS) were detected earlier in walking, coordination, and...

Risk also associated with brain volume measures A points-based cardiovascular risk score paralleled cognitive decline, a study of older adults found.Over a median 5.8 year follow-up, baseline Framingham General Cardiovascular...

Framingham Offspring Cohort study suggests older adults reap neuroprotective benefits from flavonoid-rich food Diets that are higher in flavonoids — including red wine, tea, or berries, for example — may reduce the...

PD measures stable or improved after autologous dopamine progenitor cell injection Skin fibroblast-derived dopaminergic progenitor cells from a Parkinson’s disease patient that were injected into his putamina showed...